Subscribe to Newsletter
Discovery & Development COVID-19, Drug Discovery

A Moonshot for COVID-19

An open-science consortium fighting for accessible COVID-19 treatments has received £8 million from the Wellcome Trust, a London-based charitable foundation focused on health research. The group, COVID Moonshot, was born in the early days of global lockdown. At that time, an international cross-section of scientists, academics, pharmaceutical research teams, and students began a collaborative race to identify new molecules that could block SARS-CoV-2 infection and to develop pills ready to roll out to those most in need of affordable medicine.

Alpha Lee, of the University of Cambridge, noted that Moonshot’s early efforts – focused on repurposing existing small molecule drugs and rapidly developing monoclonal antibodies – have now shifted to developing new antiviral therapeutics in light of the likely persistence of COVID-19 as a global threat.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Angus Stewart

Associate Editor of The Medicine Maker

Between studying for my English undergrad and Publishing master's degrees I was out in Shanghai, teaching, learning, and getting extremely lost. Now I'm expanding my mind down a rather different rabbit hole: the pharmaceutical industry. Outside of this job I read mountains of fiction and philosophy, and I must say, it's very hard to tell who's sharper: the literati, or the medicine makers.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine